Ontario Update
The Ontario Drug Benefit (ODB) Formulary / Comparative Drug Index (Formulary) has been updated and becomes effective April 27, 2017. The highlights are noted below:
New Limited Use (LU) products:
Entresto (sacubitril & valsartan) for the treatment of heart failure (Novartis)
Creon Minimicrospheres (pancrelipase) as replacement therapy for pancreatic insufficiency (BGP Pharma)
Product with revised Limited Use criteria:
Brilinta (ticagrelor) for treatment of myocardial infarctions or unstable angina (AstraZeneca)
New Facilitated Access product:
Genvoya (elvitegravir & cobicistat & emtricitabine & tenofovir) for treatment of HIV (Gilead) with therapeutic notes
New Exceptional Access Program (EAP) products:
Entyvio (vedolizumab) for treatment of Ulcerative Colitis and Crohn’s Disease (Takeda)
Jadenu (deferasirox) for treatment of chronic iron overload (Novartis)
Xolair (omalizumab) for the treatment of chronic idiopathic urticaria (Novartis)
New Drug Funding Program products:
Opdivo (nivolumab) for treatment of renal cell carcinoma, non-small cell lung cancer and unresectable or metastatic BRAF wild-type melanoma (Bristol Myers Squibb)
A more detailed summary of these changes and associated ODB criteria can be found on Ontario’s website at: http://www.health.gov.on.ca/en/pro/programs/drugs/formulary42/summary_edition42_20170420.pdf
To receive updates similar to this one please be sure to sign up for Market Access Signals, our free e-mail newsletter service.
